Aphria’s Fourth-Quarter Results Show It Still Has a Lot to Prove

Is Aphria (TSX:APHA)(NASDAQ:APHA) the last great hope of cannabis stocks? And is its stock a buy after its fourth quarter earnings report?

| More on:
edit Jars of marijuana

Image source: Getty Images

Any stock that sees single-day losses in the double digits is in trouble in the current market. Wednesday saw Aphria (TSX:APHA)(NASDAQ:APHA) down 18.7% despite some encouraging news in its fourth quarter. A decidedly mixed fourth quarter saw Aphria report a rise in revenue, but ultimately record a net loss of $98.8 million. While quarterly EBITDA growth is encouraging, Aphria clearly still has a lot to prove to investors going forward.

A standout stock in a saturated market

Aphria’s divisive fiscal Q4 comes at a time when mergers and acquisitions could be the next logical step for survival in the overcrowded cannabis space. In fact, consolidation might be the only sure route to long-term market dominance in a patchy legal marijuana market.

The legal weed retail environment never really took off post-legalization. Meanwhile, little headway has been made when it comes to taking on the black and grey markets.

All of this leaves little room for individual cannabis stocks to appreciate. Even Cannabis 2.0 was a muted affair. This is especially troublesome in a new and characteristically uneven industry. In fact, this space is so uneven that indexing doesn’t really work with Canadian pot stocks.

Instead, investors need to pick leading cannabis stocks that outperform their peers. This essentially counts out low-risk buyers and makes Canadian cannabis a stock-picker’s market.

But if the way forward in this country is for cannabis producers to team up, the logic in picking individual stocks for eventual market dominance falls apart. For instance, an investor in cash-rich Producer A might see their star company team up with unprofitable Producer B.

If the latter is a stock which the investor has been avoiding like the plague, then that careful investment thesis (based on profitability in this scenario) is ruined.

Looking beyond Aphria’s fourth quarter

Aphria and Aurora (TSX:ACB)(NYSE:ACB) reportedly walked away from merger talks recently. A mega-company with a third of the Canadian market share might have been an exciting prospect. Given an optimal retail environment, such a company might have been expected to rake in close to $1 billion in sales per year.

In addition, it would have had an international footprint that reached somewhere in the region of 25 countries.

But these two businesses are arguably not all that compatible. Aphria generates a lot of its own revenue from the medicinal marijuana market in Germany, for instance. While reliability and predictability from such sales go a long way to establishing shareholder trust, the pharma angle doesn’t have a huge markup. Couple this with Aurora’s major MedReleaf boo-boo and these two names don’t really mesh that well.

As a speculative play, a bargain basement Aphria investment might appeal to the long-term investor. However, a net loss and missed analyst estimates ultimately outweighed a fourth quarter rise in revenue this week, so far as its share price performance was concerned.

Against the backdrop of a disappointing retail environment and crushing market forces, even Aphria is unlikely to recover cannabis momentum single-handedly.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »